Overview

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study was aimed to evaluate efficacy and tolerability of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting in chemotherapy-naive patients after highly emetogenic chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
China Medical University, China
Collaborators:
Anshan Tumor Hospital
General Hospital of Shenyang Military Region
Liaoning Tumor Hospital & Institute
Liaoyang Central Hospital
Petrochemical General Hospital of Liaoyang city
Shengjing Hospital
The First Affiliated Hospital of Dalian Medical University
The First Hospital of Liaoning Medical University
The Second Affiliated Hospital of Dalian Medical University
Third People's hospital Liaoyang
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Palonosetron
Thalidomide